In Vivo N-Methyl-d-Aspartate Receptor (NMDAR) Density as Assessed Using Positron Emission Tomography During Recovery From NMDAR-Antibody Encephalitis

Marian Galovic; Adam Al-Diwani; Umesh Vivekananda; Matthew C Walker; Sarosh R Irani; Matthias J Koepp; NEST Investigators

doi:10.1001/jamaneurol.2022.4352

In Vivo N-Methyl-d-Aspartate Receptor (NMDAR) Density as Assessed Using Positron Emission Tomography During Recovery From NMDAR-Antibody Encephalitis

JAMA Neurol. 2023 Feb 1;80(2):211-213. doi: 10.1001/jamaneurol.2022.4352.

Authors

Marian Galovic¹, Adam Al-Diwani², Umesh Vivekananda³, Matthew C Walker³, Sarosh R Irani², Matthias J Koepp³; NEST Investigators

Affiliations

¹ Department of Neurology, Clinical Neuroscience Center, University Hospital Zurich, Zurich, Switzerland.
² Oxford Autoimmune Neurology Group, Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, United Kingdom.
³ Department of Clinical and Experimental Epilepsy, UCL Queen Square Institute of Neurology, University College London, London, United Kingdom.

No abstract available

Plain language summary

This case-control study uses a radiotracer and positron emission tomography to assess N-methyl-d-aspartate receptor (NMDAR) density changes during recovery from NMDAR-antibody encephalitis.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Anti-N-Methyl-D-Aspartate Receptor Encephalitis* / diagnostic imaging
Autoantibodies
Encephalitis*
Humans
Positron-Emission Tomography / methods
Receptors, N-Methyl-D-Aspartate

Substances

Receptors, N-Methyl-D-Aspartate
Autoantibodies

Plain language summary

Publication types

MeSH terms

Substances

Grants and funding